Ngā hua rapu - Hans‐Henrik Parving

Whakamahine hua
  1. 1
    Diabetic nephropathy: Prevention and treatment

    Diabetic nephropathy: Prevention and treatment mā Hans‐Henrik Parving

    I whakaputaina 2001
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Transcapillary Escape Rate of Albumin and Plasma Volume in Essential Hypertension

    Transcapillary Escape Rate of Albumin and Plasma Volume in Essential Hypertension mā Hans‐Henrik Parving, Finn Gyntelberg

    I whakaputaina 1973
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Diabetic Nephropathy

    Diabetic Nephropathy mā Lionel H. Opie, Hans‐Henrik Parving

    I whakaputaina 2002
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Carta
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Genetics of diabetic nephropathy.

    Genetics of diabetic nephropathy. mā Hans‐Henrik Parving, Lise Tarnow, Peter Rossing

    I whakaputaina 1996
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Risk Factors for Development of Incipient and Overt Diabetic Nephropathy in Type 1 Diabetic Patients

    Risk Factors for Development of Incipient and Overt Diabetic Nephropathy in Type 1 Diabetic Patients mā Peter Rossing, Philip Hougaard, Hans‐Henrik Parving

    I whakaputaina 2002
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Progression of microalbuminuria in type 1 diabetes: Ten-year prospective observational study

    Progression of microalbuminuria in type 1 diabetes: Ten-year prospective observational study mā Peter Rossing, Philip Hougaard, Hans‐Henrik Parving

    I whakaputaina 2005
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Kidney Function During and After Withdrawal of Long-Term Irbesartan Treatment in Patients With Type 2 Diabetes and Microalbuminuria

    Kidney Function During and After Withdrawal of Long-Term Irbesartan Treatment in Patients With Type 2 Diabetes and Microalbuminuria mā Steen Andersen, Jens Brøchner‐Mortensen, Hans‐Henrik Parving

    I whakaputaina 2003
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients

    Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients mā Per K. Christensen, Henrik Post Hansen, Hans‐Henrik Parving

    I whakaputaina 1997
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Microalbuminuria as an Early Marker for Cardiovascular Disease

    Microalbuminuria as an Early Marker for Cardiovascular Disease mā Dick de Zeeuw, Hans‐Henrik Parving, Robert H. Henning

    I whakaputaina 2006
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review

    Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review mā Frederik Persson, Morten Lindhardt, Peter Rossing, Hans‐Henrik Parving

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy

    Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy mā Peter Hovind, Lise Tarnow, Per B. Oestergaard, Hans Henrik Parving

    I whakaputaina 2000
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Renoprotective Effects of Adding Angiotensin II Receptor Blocker to Maximal Recommended Doses of ACE Inhibitor in Diabetic Nephropathy

    Renoprotective Effects of Adding Angiotensin II Receptor Blocker to Maximal Recommended Doses of ACE Inhibitor in Diabetic Nephropathy mā Kasper Rossing, Peter Karl Jacobsen, Lotte Pietraszek, Hans‐Henrik Parving

    I whakaputaina 2003
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes

    Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes mā Peter Gæde, Henrik Lund‐Andersen, Hans‐Henrik Parving, Oluf Pedersen

    I whakaputaina 2008
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

    Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes mā Hans‐Henrik Parving, Hiddo J. Lambers-Heerspink, Dick de Zeeuw

    I whakaputaina 2016
    Whiwhi kuputuhi katoa
    Carta
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria

    Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria mā Steen Andersen, Harald Mischak, Petra Zürbig, Hans‐Henrik Parving, Peter Rossing

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy

    Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy mā Peter Hovind, Lise Tarnow, Peter Rossing, Bendix Carstensen, Hans‐Henrik Parving

    I whakaputaina 2004
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study

    Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study mā M.-A. Gall, Philip Hougaard, K. Borch‐Johnsen, Hans‐Henrik Parving

    I whakaputaina 1997
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Progression of diabetic nephropathy

    Progression of diabetic nephropathy mā Peter Hovind, Peter Rossing, Lise Tarnow, U. Smidt, Hans‐Henrik Parving

    I whakaputaina 2001
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients

    Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients mā Hans-Henrik Parving, E. Hommel, Berit R. Jensen, Henrik Post Hansen

    I whakaputaina 2001
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively11See Editorial by Steffes, p. 378

    Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively11See Editorial by Steffes, p. 378 mā Peter Hovind, Peter Rossing, Lise Tarnow, U. Smidt, Hans‐Henrik Parving

    I whakaputaina 2001
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: